ArticleInflammation2015
Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis.
Article in Inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Biomarkers in psoriatic arthritis: A meta-analysis and systematic review.Frontiers in immunology · 2022Pooled it
- Harnessing tumor immune checkpoints for autoimmune disease therapeutics.Frontiers in immunology · 2026Review
- Insufficient PD-1 expression during active autoimmune responses: a deep single-cell proteomics analysis in inflammatory arthritis.Frontiers in immunology · 2024Article
- Biologics targeting IL-17 sharply reduce circulating T follicular helper and T peripheral helper cell sub-populations in psoriasis.Frontiers in immunology · 2024Article
- The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis.Journal of clinical medicine · 2023Article
- PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review.Postepy dermatologii i alergologii · 2021Review
- Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy.Mediterranean journal of rheumatology · 2021Article
- Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.Frontiers in cell and developmental biology · 2021Review
- Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia.International journal of general medicine · 2021Article
- Systemic Sclerosis Perturbs the Architecture of the Immunome.Frontiers in immunology · 2020Article
- Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis.Postepy dermatologii i alergologii · 2018Article
- [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2018Article
- Percentages of PD-1Human vaccines & immunotherapeutics · 2018Article
- Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2018Article
- Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2017Review
- The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.Bulletin of the Hospital for Joint Disease (2013) · 2017Review
- Suppressed Programmed Death 1 Expression on CD4Mediators of inflammation · 2017Article
- Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Nature reviews. Rheumatology · 2016Review
- Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.Indian journal of pharmacologyArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Programmed death-1 (PD-1) is an inhibitory co-receptor that is highly expressed in T lymphocytes that has been shown to downregulate inflammatory responses in several inflammatory diseases including systemic lupus erythematosus and rheumatoid arthritis. Yet, the role of PD-1 in psoriatic arthritis (PsA) has not been studied. In order to fill this gap, we measured the expression levels of PD-1 in peripheral T cells from patients with active disease. Twenty patients and fifteen age-matched healthy control subjects were recruited. The percentage of CD3(+)PD-1(+) T cells was measured by flow cytometry. Despite normal concentration of peripheral T cells, the expression levels of PD-1 were significantly higher in patients compared to healthy controls. Interestingly, among the patients, the expression levels inversely correlated with disease activity measured by disease activity scores (DAS28). PD-1 expression levels strongly correlated with the number of tender and swollen joints, but not with C-reactive protein (CRP) levels or psoriasis area and severity index (PASI). Functionally, in vitro ligation of PD-1 receptor in PsA T cells inhibited interleukin-2 (IL-2) secretion, Akt phosphorylation, and Rap1 activation. These findings suggest that PD-1 might serve as a biomarker for disease activity in PsA and highlight the need for additional studies in order to establish the role of PD-1 in PsA pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.